GHS-R1a comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with C-terminal amide |
| Average mass | Approximately 711.9 Da | Value derived from the formula |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and aqueous acetonitrile | Dissolution aided by acidic diluents |
| Common synonyms | Ipamorelin; NNC 26-0161 | Code name used in early reports |
在 GHS 家族中，早期肽类如 GHRP-6 与 GHRP-2 会同时促进生长激素、皮质醇与催乳素的释放，并明显增加食欲。Ipamorelin 在动物与早期人体研究中表现出对生长激素释放的相对选择性，对上述其他激素的影响较小。这种差异通常归因于受体结合模式与下游信号偏向的不同，而完整的分子解释仍有待补充。需要区分的是，选择性是研究观察中的相对程度，并非绝对界限。
从用途定位看，ipamorelin 目前主要以研究用肽的身份被讨论，未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用，不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小，因此对其效应强度与一致性的描述应保持谨慎。
Ipamorelin 是一种合成五肽，序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2，分子式 C38H49N9O5，游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素（GHS）家族，作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道，设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
"The social and psychological functions of popular music [are that it] acts like a social cement" "to keep people obedient and subservient to the status quo of existing power structures." Serious music, according to Adorno, achieves excellence when its whole is greater than the sum of its parts. The example he gives is that of Beethoven's symphonies: "[his] greatness shows itself in the complete subordination of the accidentally private melodic elements to the form as a whole." Standardization not only refers to the products of the culture industry but also to the consumers as well. Many times every day consumers are bombarded by media advertising. Consumers are pushed and shoved into consuming products and services presented to them by a media system that takes advantage of musical hooks mass-produced via electronic media. The masses have become conditioned by the culture industry, which makes the impact of standardization far more widespread. Not recognizing the impact of social media and commercial advertising, the individual is caught in a situation where conformity is the norm: "During consumption, the masses become characterized by the commodities which they use and exchange among themselves." Tony Waters and David Philhour have tested Adorno's ideas and used musical intros from pop songs and asked students in the United States, Germany, and Thailand what they recognize. They found that indeed, as Adorno hypothesized, song intro recognition has spread around the world for some specific commercial pop songs.
==== Lithium ==== The chemistry of lithium shows several differences from that of the rest of the group as the small Li+ cation polarises anions and gives its compounds a more covalent character. Lithium and magnesium have a diagonal relationship due to their similar atomic radii, so that they show some similarities. For example, lithium forms a stable nitride, a property common among all the alkaline earth metals (magnesium's group) but unique among the alkali metals. In addition, among their respective groups, only lithium and magnesium form organometallic compounds with significant covalent character (e.g. LiMe and MgMe2). Lithium fluoride is the only alkali metal halide that is poorly soluble in water, and lithium hydroxide is the only alkali metal hydroxide that is not deliquescent. Conversely, lithium perchlorate and other lithium salts with large anions that cannot be polarised are much more stable than the analogous compounds of the other alkali metals, probably because Li+ has a high solvation energy. This effect also means that most simple lithium salts are commonly encountered in hydrated form, because the anhydrous forms are extremely hygroscopic: this allows salts like lithium chloride and lithium bromide to be used in dehumidifiers and air-conditioners.
=== Nosocomial infections === Clostridioides difficile, gram-positive bacteria species that inhabits the gut of mammals, exemplifies one type of bacteria that is a major cause of death by nosocomial infections. When symbiotic gut flora populations are disrupted (e.g., by antibiotics), one becomes more vulnerable to pathogens. The rapid evolution of antibiotic resistance places an enormous selective pressure on the advantageous alleles of resistance passed down to future generations. The Red Queen hypothesis shows that the evolutionary arms race between pathogenic bacteria and humans is a constant battle for evolutionary advantages in outcompeting each other. The evolutionary arms race between the rapidly evolving virulence factors of the bacteria and the treatment practices of modern medicine requires evolutionary biologists to understand the mechanisms of resistance in these pathogenic bacteria, especially considering the growing number of infected hospitalized patients. The evolved virulence factors pose a threat to patients in hospitals, who are immunocompromised from illness or antibiotic treatment. Virulence factors are the characteristics that the evolved bacteria have developed to increase pathogenicity. One of the virulence factors of C. difficile that largely constitutes its resistance to antibiotics is its toxins: enterotoxin TcdA and cytotoxin TcdB. Toxins produce spores that are difficult to inactivate and remove from the environment. This is especially true in hospitals where an infected patient's room may contain spores for up to 20 weeks.
Sources: en.wikipedia.org
At the Game Developers Conference in March 2015, Valve and Taiwanese electronics company HTC unveiled SteamVR and the HTC Vive—a virtual reality platform and a virtual reality headset. The platform would be distinguished by its "Lighthouse" motion tracking system, where sensors on the headset and its included motion controllers read the position of two base station devices mounted in the play area. This would allow for "room-scale" VR experiences, where the player would not be required to remain in a stationary position in front of a camera and would be able to freely walk around the space. In November 2017, Microsoft added beta support for the SteamVR service for Windows Mixed Reality headsets. In June 2019, Valve released its own VR headset, known as the Valve Index, positioned as a higher-end device with wider field of view and higher refresh rate. They were accompanied by updated motion controllers, which are strapped against the user's palms and have sensors to detect input pressure and individual fingers. In November 2025, Valve announced the Steam Frame, a standalone VR headset.
== Requirements == The formal requirements to begin gender-affirming hormone therapy vary widely depending on geographic location and specific institution. Gender-affirming hormones can be prescribed by a wide range of medical providers including, but not limited to, primary care physicians, endocrinologists, and gynecologists. Requirements to be prescribed these hormones generally include a minimum age. According to the Endocrine Society, there has been little research on taking cross-sex hormones before the age of about 14. Historically, many health centers required a psychiatric evaluation and/or a letter from a therapist before beginning hormone replacement therapy. Many centers now use an informed consent model that does not require any routine formal psychiatric evaluation, but rather focuses on reducing barriers to care while ensuring a person can understand the risks and benefits of treatment. Some LGBT health organizations, including Chicago's Howard Brown Health Center and Planned Parenthood, advocate for this type of informed consent model. The World Professional Association for Transgender Health (WPATH) Standards of Care, 7th edition, note that both of these approaches to care are appropriate.
Neither of these ocular signs should be confused with exophthalmos (protrusion of the eyeball), which occurs specifically and uniquely in hyperthyroidism caused by Graves' disease (note that not all exophthalmos is caused by Graves' disease, but when present with hyperthyroidism is diagnostic of Graves' disease). This forward protrusion of the eyes is due to immune-mediated inflammation in the retro-orbital (eye socket) fat. Exophthalmos, when present, may exacerbate hyperthyroid lid-lag and stare.
=== Nonalcoholic fatty liver disease === Supplemental vitamin E significantly reduced elevated liver enzymes, steatosis, inflammation and fibrosis, suggesting that the vitamin may be useful for treatment of nonalcoholic fatty liver disease (NAFLD) and the more extreme subset known as nonalcoholic steatohepatitis (NASH) in adults, but not in children.
Sources: en.wikipedia.org
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.
It has not received marketing approval as a medicine in the United States or the European Union. Supplied material is generally described and handled as a research chemical. Regulatory treatment varies by jurisdiction, and some countries restrict growth hormone secretagogues under sports or medicines legislation.
Earlier secretagogues were associated with broader hormonal responses, including measurable changes in cortisol and prolactin. Reports on this peptide describe a narrower profile in which growth hormone release is the most prominent effect. The observation is influential because it shapes how the compound is compared with other members of the same receptor family.
It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.